NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Deutsche from Hold to Buy. Company has completed its accounting review and has a strong long-term growth outlook. $51 price target.
upgraded at Credit Suisse to Outperform from Neutral on valuation and expected stronger earnings. Price target lifted to $280. 2010 and 2011 EPS estimates raised to $11.36 and $13.50, respectively.
upgraded at Sterne Agee from Neutral to Buy. $79 price target. Company had an upbeat analyst meeting and should begin returning more cash to investors.
upgraded at Goldman from Sell to Neutral. Stock also removed from the Conviction List. Company will be a big winner from desktop virtualization. $52 price target.
downgraded at Credit Suisse to Underperform from Neutral on rising rig-on-rig competition. Price target reduced to $79 from $86. 2010 and 2011 EPS estimates lowered to $8.25 and $7.30, respectively.
Jack in the Box
upgraded at Goldman from Neutral to Buy. $27 price target. Estimates also raised, as margins are near a bottom.
STOCK COMMENTS / EPS CHANGES
added to Conviction Buy List at Goldman Sachs. Company is in the early stages of operating margin improvement. $35 price target.
target, estimates boosted at BofA/Merrill. ALB price target raised to $48 from $42 on polymer additives and catalysts. Estimates increased through 2012. Maintain Buy rating.
estimates lowered at FBR through 2011. Company is seeing weaker trading activity. Outperform rating.
Abercrombie & Fitch
numbers boosted at Jesup & Lamont. Shares of ANF now seen reaching $55. Estimates also raised, because of higher sales. Buy rating.
estimate changed at Barclays. ARIA 2010 EPS estimate introduced at -$0.57. Maintain Overweight rating and $7 price target.
estimates, target boosted at UBS. Shares of BMRN now seen reaching $26. Estimates also raised, as GALNS data continues to come in positive. Buy rating.
target, estimates boosted at Barclays to $74 from $64 after positive analyst day. 2010 and 2011 EPS estimates raised to $2.50 and $4.25, respectively. Maintain Overweight rating.
cut from Conviction Buy List at Goldman. CMI was removed from the Conviction Buy List. Stock is up 39% since December, but should continue to benefit from new engine regulations. Buy rating and $68 price target.
estimate cut at Barclays. 2010 EPS estimate lowered to 50 cents following 1Q10 results. Maintain Overweight rating and $18 price target.
estimates raised at UBS EM estimates were upped through 2011. Company winning new clearinghouse contracts. Buy rating and $22 price target.
estimates increased at FBR. Its 2010 estimates were raised because of strength in the advertising market. Strong dollar is also helping the company. Outperform rating and $810 price target.
estimates, target boosted at FBR. Shares of GR now seen reaching $80. Estimates also raised, because of improving industry fundamentals. Outperform rating.
estimates cut at FBR through 2011. Company is selling new stock to pay back TARP. Market Perform rating and $29 price target.
cut from Focus List at Goldman Sachs. Management believes that the award environment is becoming more positive. Sell rating and $35 price target.
target, estimates cut at BofA/Merrill. KMB price target reduced to $70 from $75 on higher pulp costs. 2010 and 2011 EPS estimates lowered to $4.80 and $5.23, respectively. Maintain Buy rating.
estimates, target raised at Citigroup. Shares of MSFT now seen reaching, $32. Estimates also boosted, because of cost-cutting. Buy rating.
target, estimates boosted at Credit Suisse. VMED price target lifted to $25 from $21. Good momentum for 2010. 2010 and 2011 EPS estimates raised to 17 cents and 60 cents, respectively. Maintain Outperform rating.
estimates upped at Goldman through 2011. Company is seeing better sales across the board. Neutral rating and $26 price target.
This article was written by a staff member of TheStreet.com.